Korea’s SK Chemicals said on Monday it has signed an exclusive deal to distribute Ongentys developed by Portugal’s pharmaceutical company BIAL for the treatment of adult Parkinson's disease patients with motor fluctuations in Korea.
Ongentys blocks one of the enzymes breaking down dopamine, helping extend the actions of drugs such as standard treatment levodopa that aims to increase the concentration of dopamine in the brain.
Patients treated with levodopa for a long time often experience movement fluctuations with reduced drug efficacy.
Ongentys indicated as an add-on therapy to preparations of levodopa boosts levodopa efficacy and improve related symptoms, according to the company.
SK Chemicals plans to file marketing approval for the drug in Korea in the first half of this year with a goal of launching in 2020.
“Ongentys will be an option to improve typical motor fluctuations of patients with Parkinson’s disease and we will be committed to improve public health by strengthening the portfolio of central nervous system medicines,” said an SK Chemicals official.
SK Chemicals` shares closed Monday down 1.88 percent at 104,500 won on the Kospi market.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
High Value Painting Exhibition "Explosive" Furniture Painting Inspiration Muse
Introduction to Toluene: Morning Analysis of Toluene Market on March 19
Introduction to Styrene: Morning Analysis of Styrene Market on March 19
Convergence and Breakthrough of Wanyi Pilan Distributor Association
Technology is the first productivity Delia added new honor
Introduction to Pure Benzene